Abonnement à la biblothèque: Guest
International Journal of Medicinal Mushrooms

Publication de 12  numéros par an

ISSN Imprimer: 1521-9437

ISSN En ligne: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer

Volume 4, Numéro 3, 2002, 8 pages
DOI: 10.1615/IntJMedMushr.v4.i3.30
Get accessGet access

RÉSUMÉ

In vitro and animal studies have established that the polysaccharide fractions of Ganoderma lucidum have potential antitumor activity and inhibitory effect on tumor metastasis. Ganopoly (crude polysaccharide fractions extracted from G. lucidum by patented technique, kindly provided by Encore International Ltd., Auckland, NZ) has demonstrated immunomodulating and tumor inhibitory effects in in vitro and mouse models. A clinical trial was conducted to evaluate the efficacy and safety of Ganopoly in patients with advanced cancer. One hundred and forty-three patients with advanced, previously treated cancer were enrolled. Eligibility criteria included confirmation of diagnosis, objectively measurable disease, Eastern Cooperative Oncology Group performance status of 0 to 2, life expectancy of 12 weeks or greater, no recent or concomitant anticancer therapy, and informed consent. Patients underwent evaluation of the extent of disease, quality of life, hematologic, biochemical, and selected immune function studies at baseline and after 6 and 12 weeks of Ganopoly therapy. Standard criteria were used to evaluate adverse events and response. Ganopoly was given orally at 1800 mg three times daily. Twenty-seven patients were not assessable for response and toxicity because they were lost to follow-up or refused further therapy before 12 weeks of treatment. Of the 100 fully assessable patients, 46 patients (32.2%) had progressive disease (PD) before or at the 6-week evaluation point (range, 5 days—6 weeks). Sixteen patients (11.2%) developed PD between 6 and 12 weeks of therapy. No objective (partial or complete) responses were observed, but 38 of 143 patients (26.6%) had stable disease (SD) for 12 weeks or more (range, 12-50 weeks). There was no significant change in the FACT-G scores in 85 assessable patients. However, palliative effects on cancer-related symptoms, such as sweating and insomnia, have been observed in many patients. In the group of patients with SD, FACT-G scores improved in 23 patients, were unchanged in 5 patients, and declined in 1 patient. Within this group, the median change from the baseline score to the 6- and 12-week score was +7.6 and +10.3 score, both statistically significant (P < 0.05). No significant changes of the selected immune function parameters were observed in 75 assessable patients. However, in the group of 32 patients with SD for 12 weeks or more, Ganopoly significantly increased lymphocyte mitogenic reactivity to concanavalin A and phytohemagglutinin by 28 ± 7.3% (P < 0.05) and significantly enhanced natural killer cell activity by 25 ± 5.9% (P < 0.05). Five adverse events (grade 1) were recorded, 3 of which were gastrointestinal (nausea, 2; diarrhea, 1). The results indicate that Ganopoly may have an adjunct role in the treatment of patients with advanced cancer, although objective responses were not observed in this study.

CITÉ PAR
  1. Pillai Thulasi G., Uma Devi P., Mushroom beta glucan: Potential candidate for post irradiation protection, Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 751, 2, 2013. Crossref

  2. Gao Yihuai, Tang Wenbo, Gao He, Chan Eli, Lan Jin, Li Xiaotian, Zhou Shufeng, Antimicrobial Activity of the Medicinal MushroomGanoderma, Food Reviews International, 21, 2, 2005. Crossref

  3. Hsu Kai-Di, Cheng Kuan-Chen, From nutraceutical to clinical trial: frontiers in Ganoderma development, Applied Microbiology and Biotechnology, 102, 21, 2018. Crossref

  4. Gao Yihuai, Tang Wenbo, Dai Xihu, Gao He, Chen Guoliang, Ye Jinxian, Chan Eli, Koh Hwee Ling, Li Xiaotian, Zhou Shufeng, Effects of Water-SolubleGanoderma lucidumPolysaccharides on the Immune Functions of Patients with Advanced Lung Cancer, Journal of Medicinal Food, 8, 2, 2005. Crossref

  5. Tang Wenbo, Gao Yihuai, Chen Guoliang, Gao He, Dai Xihu, Ye Jinxian, Chan Eli, Huang Min, Zhou Shufeng, A Randomized, Double-Blind and Placebo-Controlled Study of aGanoderma lucidumPolysaccharide Extract in Neurasthenia, Journal of Medicinal Food, 8, 1, 2005. Crossref

  6. Prabhu Sunil, Huang Ying, Wang Jeffrey, Evidence-based Materia Medica for Cancer Chemoprevention, in Materia Medica for Various Cancers, 2, 2012. Crossref

  7. Ahmed Hammad, Aslam Muhammad, Evaluation of aphrodisiac activity of ethanol extract of Ganoderma lucidum in male Wistar rats, Clinical Phytoscience, 4, 1, 2018. Crossref

  8. Ahmad Md Faruque, Ganoderma lucidum: A rational pharmacological approach to surmount cancer, Journal of Ethnopharmacology, 260, 2020. Crossref

  9. Zhao Shuang, Gao Qi, Rong Chengbo, Wang Shouxian, Zhao Zhekun, Liu Yu, Xu Jianping, Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products, Journal of Fungi, 6, 4, 2020. Crossref

  10. Shetab Boushehri Maryam A., Lamprecht Alf, TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings, Molecular Pharmaceutics, 15, 11, 2018. Crossref

  11. Ahmad Md Faruque, Ganoderma lucidum: Persuasive biologically active constituents and their health endorsement, Biomedicine & Pharmacotherapy, 107, 2018. Crossref

  12. Do Dat Tran, Lam Dang Hoang, Nguyen Tai, Phuong Mai Tran Thi, Phan Le Thao My, Vuong Hoai Thanh, Nguyen Duc Viet, Linh Ngo Thi Thuy, Hoang Minh Nam, Mai Thanh Phong, Nguyen Huu Hieu, Sarkar Nirmal Kumar, Utilization of Response Surface Methodology in Optimization of Polysaccharides Extraction from Vietnamese Red Ganoderma lucidum by Ultrasound-Assisted Enzymatic Method and Examination of Bioactivities of the Extract, The Scientific World Journal, 2021, 2021. Crossref

  13. Ahmad Rizwan, Riaz Muhammad, Khan Aslam, Aljamea Ahmed, Algheryafi Mohammad, Sewaket Deya, Alqathama Aljawharah, Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties , Phytotherapy Research, 35, 11, 2021. Crossref

4059 Vues d'articles 36 Téléchargements d'articles Métrique
4059 VUES 36 TÉLÉCHARGEMENTS 13 Crossref CITATIONS Google
Scholar
CITATIONS

Articles avec un contenu similaire:

A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) Extract in Patients with Type II Diabetes Mellitus International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 1
Jin Lan, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Yellow Brain Culinary-Medicinal Mushroom, Tremella mesenterica Ritz.:Fr. (Higher Basidiomycetes), is Subjectively but not Objectively Effective for Eradication of Helicobacter pylori: A Prospective Controlled Trial International Journal of Medicinal Mushrooms, Vol.14, 2012, issue 1
Ronit Gafni-Schieber, Solomon P. Wasser, Jesse Lachter, Yevgeny Yampolsky
Immune Responses to Water-Soluble Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) P. Karst. Polysaccharides in Patients with Advanced Colorectal Cancer International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Min Huang, Eli Chan, Wenbo Tang, Shufeng Zhou, Xihu Dai
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain